

CONTENTS

INTRODUCTION

1 A History of Melanoma: From Hunter to Milton 1

Arthur J. Sober, Helen M. Shaw, John F. Thompson

John Hunter (1728-1793)
René Laennec (1781-1826)
William Norris (1792-1877)
Oliver Pemberton (1825-1897)
James Paget (1814-1899)
Sir Jonathan Hutchinson (1828-1913)
William Sampson Handley (1872-1962)
Alexander Breslow (1928-1980)
Vincent J. McGovern (1915-1983)
Sophie Spitz (1910-1956)
Arthur Allen (1910-1994)
Wallace H. Clark, Jr. (1924-1997)
Thomas B. Fitzpatrick, Jr. (1919-2003)
Gerald W. Milton (1924-2007)

PART I

EPIDEMIOLOGY, PROGNOSIS, AND STAGING

2 Epidemiology of Melanoma 17

Bruce K. Armstrong, Alisa M. Goldstein

Worldwide incidence and mortality patterns
Correlates of melanoma risk
 Demographic correlates
 Constitutional correlates
 Environmental and behavioral correlates
Present and future trends in melanoma incidence and mortality

3 Prognostic Factors and Natural History of Melanoma 35

Jeffrey E. Gershenwald, Charles M. Balch, Seng-jaw Soong, John F. Thompson

AJCC melanoma staging system analyses—
 overview of the AJCC international melanoma database and 2002 melanoma staging system
Background
 Overview of the 2002 (sixth edition) AJCC melanoma database and melanoma staging system
Validation of the AJCC melanoma staging system
 Prognostic factors in primary melanoma (stages I and II)
 Prognostic factors in regionally metastatic melanoma: lymph node metastases, satellite lesions, and in-transit metastases
 AJCC melanoma database: multivariate analysis for stage III patients
 Prognostic factor analyses in patients with distant metastatic melanoma (stage IV)
 AJCC melanoma database analysis: stage IV

4 Melanoma Staging and Classification 65

Charles M. Balch, Jeffrey E. Gershenwald, Seng-jaw Soong, Arthur J. Sober, John M. Kirkwood

Anatomy
 Primary sites
 Regional lymph nodes
 Metastatic sites
Rules for classification
 Clinical staging
 Pathologic staging
 Clinical versus pathologic staging

- TNM classification
 - Primary tumor (T)
 - Regional lymph nodes (N)
 - Distant metastatic melanoma (M)
- Staging recommendations for metastases from unknown primary site
- Stage groupings
- Data-recording criteria

5 Models for Predicting Melanoma Outcome, 87

Seng-jaw Soong, Shouluan Ding, Daniel G. Coit, Charles M. Balch

- Description of the statistical model
 - Hazard function
 - Survival function
- Predicting outcome from initial diagnosis for patients with localized melanoma
 - Hazard function estimation and parametric modeling for localized melanoma
- Predicting outcome from initial diagnosis for patients with regional melanoma
- Predicting outcome after a disease-free interval in patients with localized melanoma
- Clinical applications
 - Clinical scoring system
 - Disease management decisions
 - Patient risk classification
 - Planning clinical trials
 - Analysis of clinical studies
 - Other applications

PART II

SCREENING: CLINICAL ASSESSMENT AND PATHOLOGY

6 Melanoma Prevention and Screening 107

J. Mark Elwood, Jennifer Kay Makin, Craig A. Sinclair, Robert Burton

- Prevention of melanoma
 - Reducing personal exposure: shade, clothing, and sunscreens
 - Intervention trials of the prevention of skin cancers and related lesions
 - Behavioral change programs for reducing personal exposure

- Vitamin D
 - Controlling exposure to sunbeds
- Prevention of melanoma: recommendations
- Screening for melanoma
 - Uncertainties and conflicts in melanoma screening
 - Evidence relating to the effectiveness of screening
 - Programs of screening
 - Challenges in the detection of progressive melanoma

7 Clinical Genetics and Risk Assessment of Melanoma 133

Graham J. Mann, Hensin Tsao

- Clinical risk assessment
 - Baseline risks attributable to age and sex
 - Previous melanoma or other skin cancer
 - Multiple melanocytic nevi
 - Skin and hair color, skin phototype, and freckling
 - Sun exposure and its surrogates
 - Family history of melanoma
- Genetic risk of melanoma
 - Mutations in CDKN2A and CDK4 in familial melanoma
 - Pancreatic cancer and other phenotypes
 - CDKN2A mutations in sporadic and multiple primary melanoma
 - Melanoma risk to CDKN2A mutation carriers
 - Low-penetrance melanoma susceptibility genes
 - Genetic testing for melanoma risk?
- Management of high-risk individuals
- The future

8 Acquired Precursor Lesions and Phenotypic Markers of Increased Risk for Cutaneous Melanoma 145

Scott W. Menzies, Hensin Tsao, Arthur J. Sober

- Pigment phenotype
 - Constitutive pigmentation (racial)
 - Hair and eye color
 - Oculocutaneous albinism
 - Ephelis (freckle)
- Moles
 - Benign (common) acquired moles (nevi)
 - Atypical moles
- Lentigo maligna

9 Clinical Characteristics of Melanoma 161*Allan C. Halpern, Ashfaq A. Marghoob, Arthur J. Sober*

- Personal history of skin cancer
- Clinical presentation
 - Signs and symptoms
 - Clinical features
 - Growth patterns
- Clinical assessment
 - History
 - Physical examinations
 - Diagnostic accuracy and aids to diagnosis
- New technologies for diagnosis
 - Image analysis for diagnosis
 - Multispectral imaging and automated diagnosis
 - Confocal scanning laser microscopy
- Other techniques: ultrasound imaging, magnetic resonance imaging, and optical coherence tomography
- Evolving paradigms in the analysis of dermoscopic images
 - How we analyze images

10 Biopsy of Suspected Melanomas 197*Nanette J. Liégeois, Timothy M. Johnson, Arthur J. Sober*

- Prebiopsy lesion assessment
- Biopsy techniques
 - Excisional biopsy
 - Incisional biopsy
 - Fine-needle aspiration
 - Frozen sections
 - Biopsy of the nail unit
 - Biopsy of the mucosa

11 Pathology of Melanoma 205*Richard Anthony Scolyer, Martin C. Mihm, Jr., Alistair J. Cochran, Klaus J. Busam, Stanley William McCarthy*

- Pathologic assessment of melanocytic tumors:
 - goals and expectations
- Biopsy techniques for clinically suspicious melanocytic tumors: the hazards of incomplete biopsies
- Pathologic examination of the primary melanoma site
- Clinical correlation for enhancement of pathologic accuracy
 - Specimen orientation
- Melanoma tumor progression: the concept of radial and vertical growth phases

- Clinicopathologic classification of melanoma
 - Superficial spreading melanoma
 - Lentigo maligna melanoma
 - Acrolentiginous melanoma
 - Nodular melanoma
- Histologic features of vertical growth phase melanoma
 - Predominantly epithelioid cell vertical growth phase
 - Predominantly spindle cell vertical growth phase
- Pitfalls
 - Mixed spindle cell and epithelioid cell vertical growth phase
 - Nevoid vertical growth phase (nevoid melanoma)
- Prognostication
 - The melanoma pathology report including a synoptic format
- Uncommon melanoma variants
 - Metastatic melanoma
 - Fine-needle biopsy in melanoma patients
 - Clear cell sarcoma (melanoma of soft parts)
 - Molecular pathology of melanoma
 - The concept of the cancer stem cell
 - The metastatic niche concept

PART III**MANAGEMENT OF LOCALIZED MELANOMA****12 Excision of Primary Melanoma 251***Merrick I. Ross*

- Excision of primary melanoma: fundamental concepts
- Historical perspective and the emergence of a contemporary paradigm
 - Thin melanoma (T1 and T2; less than 2 mm) excision trials
 - The Intergroup Melanoma Surgical Trial (T2 and T3 melanomas; 1 to 4 mm)
 - Thicker melanoma (T3 and T4; greater than 2 mm) excision trials
- Current recommendations
 - Excisions for histologic variants
 - Techniques for routine wound closure
 - Excisions for melanomas in unusual or restrictive locations

13 Complex Closures of Melanoma

Excisions 275

*Maurice Y. Nahabedian, Jonathan R. Stretch,
Anthony P. Tufaro*

Principles of reconstructive surgery
Assessment of the acquired defect
Reconstructive options for complex wounds

Definitions
Undermining with primary closure
Skin grafts
Composite grafts
Local flaps
Regional flaps
Free tissue transfer
Tissue expansion

Complex closures: regional considerations and clinical application

Head and neck
Trunk
Extremities

Surgical salvage for extensive and recurrent melanoma

14 Local Recurrences of Melanoma and Their Management 323

Kenneth K. Tanabe, Douglas S. Reintgen, Charles M. Balch

Definition
Mechanisms
Risk factors for local recurrence
Surgical margins and local recurrence
Sentinel node biopsy and local recurrence
Timing of local recurrences
Local recurrence and survival
Management

15 Mucosal Melanoma 337

Merrick I. Ross, Michael A. Henderson

Epidemiology
Pathologic features and diagnosis
Staging and prognosis
Mucosal melanomas in the head and neck

Epidemiology
Clinical presentation
Differential diagnosis
Prognosis and natural history
Treatment

Mucosal melanomas in the female genital tract

Vulvar melanoma
Vaginal melanoma
Treatment

Anorectal mucosal melanomas
Clinical and pathologic features
Treatment

Mucosal melanomas at other sites
Urinary tract
Esophagus
Role of radiotherapy

16 Melanoma in Children and Teenagers 351

*Julie R. Lange, Ira J. Dunkel, Helen M. Shaw,
Arthur J. Sober*

Epidemiology
Congenital melanoma
Precursors and risk factors
Giant congenital nevi
Small and medium congenital nevi
Xeroderma pigmentosum
Constitutional risk factors
Ultraviolet exposure

Clinical presentation
Diagnosis and surgical management
Medical management

Interferon
Vaccine trials
Chemotherapy

Outcomes
Follow-up and surveillance

17 Pregnancy and the Use of Hormones in Melanoma Patients 363

Rona M. MacKie

Nevi and pregnancy
Pregnancy before melanoma
Melanoma before pregnancy
Melanoma during pregnancy
Effect of pregnancy on disease outcome
Transplacental metastases
Treatment of melanoma during pregnancy
Surgery
Adjuvant nonsurgical therapy for pregnant women
Chemotherapy
Oral contraception and melanoma
Use of oral contraception and subsequent risk of melanoma
Use of oral contraceptives after treatment for melanoma

Hormone replacement therapy and melanoma
 Appropriate advice on planning pregnancy after
 treatment for melanoma
 In vitro fertilization and melanoma

PART IV

MANAGEMENT OF REGIONAL METASTASES

18 The Sentinel Lymph Node and Regional Melanoma Micrometastases 373

Donald L. Morton, Alistair J. Cochran, John F. Thompson, Vernon K. Sondak

The history and conceptual basis of sentinel node biopsy
 Anatomic versus functional definitions of the sentinel lymph node
 Incubator versus marker theory
 Immunology of the sentinel node
 Pathobiology of tumor-induced immunosuppression of the sentinel node
 Sentinel node biopsy for staging clinically localized melanoma
 Interim results of the first Multicenter Selective Lymphadenectomy Trial
 Survival
 Should lymphatic mapping and sentinel node biopsy be the standard of care for cutaneous melanoma?
 LM/SNB increases the chance of remaining disease free
 LM/SNB is a superior staging technique for identifying appropriate candidates for adjuvant therapy
 No noninvasive staging alternative is available
 Early treatment of patients with a positive sentinel node may improve survival
 “False-positivity” does not apply to the sentinel node
 LM/SNB for melanomas that are not intermediate in thickness
 Unresolved issues and ongoing research
 The second Multicenter Selective Lymphadenectomy Trial
 Carbon particle mapping

19 Lymphoscintigraphy in Patients With Melanoma 387

Roger F. Uren, John F. Thompson, Brendon J. Coventry, Barry E. Chatterton

Definition of a sentinel node
 Lymphatic mapping of the skin: early studies
 Lymphoscintigraphy
 The first radiocolloid and early experience with lymphoscintigraphy
 Radiopharmaceuticals
^{99m}Tc-labeled colloids
^{99m}Tc-antimony sulfide colloid
^{99m}Tc-rhenium sulfide colloid and ^{99m}Tc-albumin nanocolloid
^{99m}Tc-sulfur colloid
^{99m}Tc-human serum albumin
 What is the ideal radiocolloid?
 Lymphoscintigraphy for sentinel lymph node biopsy procedures
 Lymphoscintigraphy technique
 Injecting the tracer
 Immediate dynamic imaging
 Delayed static imaging
 Unexpected lymphatic drainage pathways
 Marking the surface location of the sentinel node
 Radiation dosimetry: risks to the patient
 Radiation dosimetry: risks to the pregnant patient
 Radiation dosimetry: risks to attending staff
 Patterns of lymphatic drainage from the skin
 Trunk
 Head and neck
 The limbs
 Interval nodes
 Drainage to multiple node fields
 Complex lymphatic drainage patterns
 Lymphoscintigraphy in clinically involved node fields
 The future
 New tracers for lymphatic mapping
 Gamma probes for intraoperative detection of radioactivity
 Gamma cameras for intraoperative imaging
 Alternate methods of lymphatic mapping

20 Intraoperative Mapping and Sentinel Node Technology in Patients With Melanoma 415

Jeffrey E. Gershenwald, John F. Thompson, Nicola Mozzillo, Charles M. Balch

- Approach to clinically negative regional lymph node basins in patients with early-stage primary cutaneous melanoma
- Rationale for lymphatic mapping and sentinel lymph node biopsy
- Technique for lymphatic mapping and sentinel lymph node biopsy
- Role of sentinel lymph node biopsy in pathologic regional lymph node staging: prognostic value of sentinel lymph node pathologic status
- Early results
- Prognostic significance
- Patterns of failure after negative sentinel lymph node biopsy
- Clinical relevance of submicroscopic disease
- Ongoing clinical trials of lymphatic mapping and sentinel lymph node biopsy
- Technical planning: overall approach
 - Patient selection
- Special situations
 - Approach to patients after previous wide local excision
 - Approach to patients with irregular lymphatic drainage patterns
 - Desmoplastic histology
 - Complications and morbidity after lymphatic mapping and sentinel lymph node biopsy
 - Technical considerations: lymphatic mapping and sentinel lymph node biopsy
 - General operating room positioning strategies

21 Axillary and Epitrochlear Lymph Node Dissection for Melanoma 447

Kelly M. McMasters, Sandra L. Wong, Douglas S. Tyler, Charles M. Balch, John F. Thompson

- Axillary dissection
 - Anatomy
 - Surgical technique
 - Operative approaches to the upper axilla for recurrent or bulky axillary metastases
 - Postoperative management
 - Complications
- Epitrochlear dissection
 - Rationale
 - Anatomy
 - Surgical technique

22 Inguinofemoral, Iliac/Obturator, and Popliteal Lymphadenectomy in Patients With Melanoma 457

Lisa K. Jacobs, Charles M. Balch, Daniel G. Coit

- Inguinofemoral dissection
 - Indications
 - Technique
 - Modifications of the classic technique of inguinofemoral lymphadenectomy
- Iliac/obturator (deep pelvic) lymph node dissection
 - Indications
 - Benefits
 - Operative technique
- Postoperative complications: incidence and risk factors
 - Complications of lymph node dissection
 - Management of postoperative complications
- Popliteal dissection
 - Indications
 - Operative technique

23 Neck Dissection and Parotidectomy for Melanoma 471

Anthony P. Tufaro, Subail K. Mithani, Joseph A. Califano III, Ashok Shaba

- Anatomy
 - Sublevels
- Patterns of metastatic spread and extent of dissection
- Neck dissection
 - Comprehensive neck dissection
 - Selective neck dissection
 - Complications
- Parotidectomy
 - Preoperative evaluation
 - Anesthesia and positioning
 - Technique
 - Complications
- Clinical outcome
- Adjuvant radiotherapy

24 Recurrent Regional Metastases of Melanoma 487

Daniel G. Coit, Cristina R. Ferrone

- In-transit metastases
 - Incidence
 - Treatment
 - Adjuvant therapy
 - Prognosis

- Recurrent nodal metastases after lymph node dissection
 - Incidence
 - Treatment
 - Prognosis
 - Adjuvant therapy
- 25 Radiotherapy for Primary and Regional Melanoma 499**
Graham Stevens, Bryan Burmeister
 - Role of radiotherapy in the management of primary melanoma
 - Adjuvant radiotherapy after surgical excision
 - Results of curative radiotherapy alone
 - Radiotherapy for lentigo maligna and lentigo maligna melanoma
 - Treatment recommendations for the use of radiotherapy in primary melanoma and lentigo maligna
 - Illustrative cases
 - Role of radiotherapy in the management of in-transit metastasis
 - Treatment recommendations for the use of radiotherapy for in-transit melanoma
 - Illustrative cases
 - Role of radiotherapy in the management of regional lymph node metastasis
 - Adjuvant postoperative radiotherapy after regional lymph node dissection
 - Results of adjuvant radiotherapy after complete lymph node dissection
 - Adjuvant radiotherapy after limited lymph node dissection
 - Preoperative radiotherapy for bulky nodal disease
 - Palliative radiotherapy for unresectable regional nodal disease
 - Treatment recommendations for the use of radiotherapy in regional nodal metastasis
 - Adjuvant radiotherapy after complete lymph node dissection
 - Adjuvant radiotherapy after limited lymph node dissection or no dissection
 - Therapeutic (palliative) radiotherapy
 - Illustrative cases
- 26 Hyperthermic Regional Perfusion for Melanoma of the Limbs 519**
H. Richard Alexander, Jr., Douglas L. Fraker, Alexander M.M. Eggermont
 - Epidemiology and natural history
 - Historical perspective and early clinical series
 - Technical aspects of isolated limb perfusion
 - Melphalan
 - Pharmacokinetics of melphalan in isolated limb perfusion
 - Other chemotherapeutic agents
 - Hyperthermia
 - Tumor necrosis factor
 - Toxicity of isolated limb perfusion
 - Adjuvant isolated limb perfusion
 - Therapeutic limb perfusion
 - Melphalan alone
 - Melphalan and tumor necrosis factor
- 27 Isolated Limb Infusion for Melanoma 541**
Georgia M. Beasley, Hidde M. Kroon, Merrick I. Ross, Peter C.A. Kam, John F. Thompson, Douglas S. Tyler
 - Similarities and differences between isolated limb infusion and conventional hyperthermic isolated limb perfusion
 - Patient selection for isolated limb infusion
 - Technical details of the isolated limb infusion procedure
 - Preoperative assessment and management
 - Insertion and positioning of arterial and venous catheters
 - Procedure in the operating room
 - Postoperative care
 - Pharmacokinetics of melphalan
 - Use of microdialysis to monitor drug concentrations in limb tissues and tumor deposits during isolated limb infusion
 - Limb and systemic toxicity after isolated limb infusion
 - Factors predicting toxicity after isolated limb infusion
 - Clinical results of isolated limb infusion
 - Factors predicting outcome after isolated limb infusion
 - Limb temperatures during isolated limb infusion
 - Tourniquet times
 - Interpretation of prognostic factors data
 - Repeat isolated limb infusion for disease progression after initial isolated limb infusion
 - Comparison with hyperthermic isolated limb perfusion
 - Laboratory studies of isolated limb infusion
 - Potential use of the isolated limb infusion technique to evaluate other drugs and biologic agents

PART V**DIAGNOSIS AND LOCAL TREATMENT OF DISTANT METASTASES****28 Metastatic Surveillance and Follow-up of Melanoma Patients 563***Julie R. Lange, Axel Hauschild, Anne Brecht Francken*

- Goals of surveillance
- Patterns of melanoma recurrence
 - Risk of local and regional recurrence
 - Time to recurrence
- Strategies for active follow-up of melanoma patients
- Detection of recurrences
- Role of physical examination
- Patient education
- Patient well-being and follow-up
- Follow-up schedules
- Radiologic studies and laboratory tests
- Screening for risk of new primary melanomas
- Screening for other primary cancers
- Current recommendations for surveillance

29 Diagnosis of Stage IV Melanoma 573*Michael B. Atkins, Axel Hauschild, Richard L. Wabl, Charles M. Balch*

- Timing of distant metastasis
- Pattern of metastasis
- Prognosis and prognostic factors
 - Sites of distant metastases
 - Number of metastatic sites
 - Elevated serum lactate dehydrogenase
 - Duration of remission
 - Performance status
 - Other prognostic factors
- Clinical evaluation of metastasis
 - History and physical examination
 - Laboratory tests/biomarkers
 - Radiologic tests
 - Pathologic tests
- Sites of distant metastases
 - Skin, subcutaneous tissues, and distant lymph nodes
 - Lung, pleura, and mediastinum
 - Brain and spinal cord
 - Gastrointestinal tract
 - Liver, biliary tract, and spleen
 - Bone
 - Kidneys and urinary tract
 - Heart and pericardium
 - Pancreas
 - Peritoneum and mesentery
 - Endocrine organs

- Breast
- Ovaries, uterus, and placenta
- Testes and penis
- Oral cavity, pharynx, and larynx
- Eye and orbit
- Cutaneous melanosis

Metastatic melanoma from an unknown primary site

Surveillance in patients who have localized melanoma

30 Surgical Excision of Distant Melanoma Metastases 603*John F. Thompson, Donald L. Morton, Charles M. Balch, Merrick I. Ross*

- Current status of surgery for stage IV melanoma
- Relationships between tumor burden, immune function, and surgical treatment
- Selection of patients and prognostic factors
- Outcomes after surgical resection of melanoma metastases at specific sites
 - Skin, subcutaneous tissue, and lymph nodes
 - Lung, trachea, and bronchi
 - Brain and spinal cord
 - Gastrointestinal tract
 - Liver, biliary tract, and spleen
 - Bone
 - Kidney and urinary tract
 - Heart and pericardium
 - Endocrine organs
 - Breast
 - Ovaries, uterus, and vagina
 - Testes and penis
 - Oral cavity and pharynx
 - Eye and orbit

31 Radiotherapy for Distant Metastases and Clinical Radiobiology of Melanoma 629*Graham Stevens, Angela Hong, Michael J. McKay*

- Radiotherapy for distant metastases
 - Skin and subcutaneous metastases
 - Lymph node metastases
 - Brain metastases
 - Malignant spinal cord compression
 - Bone metastases
 - Sites irradiated less commonly
 - Developing sites for focused radiation treatment
 - Illustrative cases
- Clinical radiobiology of melanoma
 - Biologic factors affecting the ionizing radiation response of melanoma
 - Intrinsic cellular radiosensitivity
 - Tumor oxygenation and microenvironmental factors

- Tumor cell proliferation kinetics
- Number of clonogenic tumor cells
- Influence of melanization on radiosensitivity
- Host factors in melanoma response and outcome
- Future possibilities
 - Methods to improve the response of melanoma cells
 - Methods to improve the delivery of radiation to melanoma metastases

32 Multidisciplinary Management of CNS Melanoma Metastases 651

Kim A. Margolin, George M. Cannon, Minesh P. Mehta, Michael Y. Chen

- Risk factors and prognosis
- Clinical features
- Neurosurgical management of brain metastasis
- Radiotherapeutic and radiosurgical management of melanoma metastatic to the brain or spine
 - Whole-brain radiotherapy
 - Whole-brain radiotherapy alone
 - Surgery followed by whole-brain radiotherapy
 - Stereotactic radiosurgery
- Systemic therapy for melanoma metastatic to the central nervous system
- Systemic therapy considerations after adequate control of the central nervous system
 - Palliative approach
 - Aggressive approach
 - Investigational approach

PART VI

SYSTEMIC TREATMENT OF METASTATIC DISEASE

33 Adjuvant Systemic Therapy for High-Risk Melanoma Patients 669

John M. Kirkwood, Vernon K. Sondak, Peter Hersey, Helen Gogas

- Who should be considered for adjuvant therapy?
- Chemotherapy alone or in multiagent combinations as adjuvant therapy for melanoma
- Microbial immunostimulants
 - Bacillus Calmette-Guérin
 - Corynebacterium parvum*
- Levamisole
- Hormonal therapy

- Melanoma vaccines tested in phase III adjuvant trials
- Adjuvant interferons as postoperative adjuvant therapy for melanoma
 - Adjuvant applications of interferon-alpha-2
 - Adjuvant applications of interferon-gamma
- Emerging new modalities of adjuvant therapy
- Biomarkers of prognosis and response

34 Chemotherapy-Based Treatment of Metastatic Melanoma 693

Michael B. Atkins, Mark R. Middleton, Paul B. Chapman

- Single-agent chemotherapy
 - Dacarbazine and temozolomide
 - Nitrosoureas
 - Platinums
 - Microtubule toxins
- Combination cytotoxic chemotherapy
 - Nitrosourea combinations
 - Taxane-based combination therapy
 - Cisplatin-based combination therapy
- Chemohormonal therapy
- Biochemotherapy
- Interferon alpha-based biochemotherapy regimens
- Interleukin-2-based regimens
 - Interleukin-2 and DTIC/temozolomide combinations
 - Cisplatin and interleukin-2-based biochemotherapy regimens
- Inpatient concurrent biochemotherapy regimens
 - Phase III biochemotherapy trials
- Other biochemotherapy investigations
 - Non-interleukin-2 or interferon-based biochemotherapy combinations
- Chemotherapy and antiangiogenic or targeted therapy
 - Antiangiogenic agents
 - Antiapoptosis-inducing agents
 - Selection of future phase III trials

35 Interferon Therapy for Melanoma 715

Ernest C. Borden, Stergios J. Moschos, John M. Kirkwood

- Endogenous interferons as part of the host response to cancer
- The family of interferon proteins and signaling activation
- Mechanisms of antitumor action in melanoma
- Signaling by interferons
- Cellular mechanisms of action of interferons
- Interferon-alpha-2 in the treatment of melanoma
- The future of interferons in melanoma biology and therapy

36 Interleukins and Cellular Therapies for Melanoma 731*Douglas J. Schwartzentruber*

- Pharmacology of interleukin-2
- Immunologic activity of interleukin-2
- Systemic effects of interleukin-2
- Clinical efficacy of high-dose interleukin-2 alone
- Clinical efficacy of alternate doses, routes, and schedules of interleukin-2 alone
- Clinical efficacy of interleukin-2 combined with interferon-alpha
- Clinical efficacy of interleukin-2 combined with other cytokines, immune modulators, antibodies, or vaccines
- Agents to reduce the toxicity of interleukin-2
- Predictors of clinical response
- Other cytokines for treatment of metastatic melanoma
- Clinical efficacy of interleukin-2 combined with cellular therapy

37 Melanoma Vaccines 757*Jedd D. Wolchok, Jeffrey S. Weber*

- Tumor immunology
- Antigen discovery
- Adjuvants
- Vaccine approaches
 - Cell vaccines
 - Transduced cell vaccines
 - HLA-restricted melanoma-associated antigenic peptides
 - Ganglioside vaccines
 - Antiidiotypic monoclonal antibodies mimicking ganglioside antigens
 - Protein antigens
 - Heat-shock protein-based vaccines
 - DNA vaccination
 - Dendritic cell vaccines
 - Recombinant viral vaccines
- Combination strategies and the future of melanoma vaccines

38 Immune Modulators in the Treatment of Patients With Melanoma 775*James P. Allison, F. Stephen Hodi, Yvonne M. Saenger, Jedd D. Wolchok*

- Biology of CTLA-4-mediated immune inhibition
- Preclinical development of anti-CTLA-4 as an anticancer agent
- Anti-CTLA-4: clinical experience in melanoma
 - Efficacy of CTLA-4 blockade: summary of clinical trials to date
 - CTLA-4 blockade and immune-related adverse events

- Kinetics of response
- Patient selection and predictors of toxicity and antitumor response
 - Dose and schedule of anti-CTLA-4 administration
- Correlative immunologic studies
- Vaccination strategies in combination with CTLA-4 blockade
 - Combination of CTLA-4 blockade and GM-CSF vaccination in murine models
 - Clinical investigation of combination CTLA-4 blockade and autologous GM-CSF-secreting tumor vaccination
 - CTLA-4 blockade with peptide vaccines
- Other CTLA-4 antibody and immunotherapy combinations

39 Melanoma-Specific Targeted Therapies 793*Paul B. Chapman, David B. Solit, Keith T. Flaherty*

- Targeting cell surface molecules
 - Targeting receptor tyrosine kinases expressed in melanoma
 - Monoclonal antibodies
- Targeting intracellular molecules
 - The mitogen-activated protein kinase pathway in melanoma
 - Drugs that inhibit BRAF
 - Hsp90 inhibitors
 - Drugs that inhibit MEK
 - Targeting PI3/AKT pathway
- Angiogenesis inhibition in melanoma

PART VII**BIOLOGY OF MELANOMA****40 Genetics and Molecular Pathology of Melanoma** 807*Boris C. Bastian, Daniel Pinkel, Amaya Viros*

- Distinct patterns of epidemiologic, clinical, and histopathologic features in melanoma
- Emerging melanoma subtypes based on genotype-phenotype correlations
 - Melanomas on sun-exposed sites
 - Melanomas on relatively or absolutely UV-protected sites
 - Melanocytic tumors arising without associations to epithelial structures

41 Biology of Melanocytes and Primary Melanoma 821*Glenn Merlino, Vincent J. Hearing*

- Development of melanoblasts
 - Regulation of specification
 - Regulation of migration
 - Regulation of survival and proliferation
- Differentiation of melanocytes
 - Regulation of differentiation
 - Regulation of survival
- Melanomagenesis
 - From melanocyte to melanoma: a multistep process
 - Molecular genetics: early lessons from familial and sporadic melanoma
 - Melanoma: a consequence of homeostatic disruption
 - Melanoma: cell of origin
- Melanoma and the environment
 - Sun exposure and epidemiology
 - Photobiology and melanoma

42 Biology of Melanoma Metastasis 847*Menashe Bar-Eli, Isaiah J. Fidler*

- The pathogenesis of melanoma metastasis
- Transcriptional regulation of melanoma progression
 - Role of AP-2- α in melanoma progression
 - Role of CREB/ATF-1 in melanoma progression
 - Involvement of ATF-2 in melanoma progression
 - SNAIL: its regulatory pathway in melanoma
 - MITF: its role in melanoma progression
- Regulation of melanoma metastasis by the tumor microenvironment
 - Role of platelet-activating factor receptor
- Potential therapeutic approaches to inhibiting melanoma metastasis
 - Using fully humanized antibodies to MCAM/MUC18 to inhibit tumor growth and metastasis of human melanoma
 - Using fully humanized neutralizing antibodies to interleukin-8 (ABX-IL-8) to inhibit angiogenesis, tumor growth, and metastasis of human melanoma

43 Immunology of Melanoma 865*Suzanne L. Topalian, Lieping Chen, Janis M. Taube, Paul F. Robbins, Jedd D. Wolchok, Alan N. Houghton*

- Innate immunity
- Adaptive immunity
- Melanoma antigens
 - General principles for identification of tumor antigens recognized by T cells and antibodies
 - Nonmutated self-antigens
 - Mutant melanoma antigens
 - Altered peptide ligands: enhancing the immunogenicity of low-affinity melanoma epitopes
- Experimental models
- Immune regulation and tolerance
 - Costimulatory/coinhibitory receptors
 - Regulatory T cells
 - Cytokines
- Implications for immunotherapy

44 Biomarkers for Melanoma 883*Elizabeth A. Grimm, Dave S.B. Hoon, Lyn McDivitt Duncan*

- Potential clinical impact of melanoma biomarkers
- Melanoma heterogeneity
- Melanoma biomarker discovery and validation process
- Biomarkers in early-stage melanoma
 - Molecular markers in primary cutaneous melanoma
- Biomarkers for later-stage melanoma
 - Molecular markers in sentinel lymph nodes
 - Molecular markers in blood
 - Molecular markers in metastatic tumors

Additional Credits 899**Index 901**